Top

The journal of nutrition, health & aging

Published in:

01-02-2020

Genetic Variants of Homocysteine Metabolism, Homocysteine, and Frailty - Rugao Longevity and Ageing Study

Authors: T. Ma, X.-H. Sun, S. Yao, Z.-K. Chen, J.-F. Zhang, W. D. Xu, Xiao-Yan Jiang, Xiao-Feng Wang

Published in: The journal of nutrition, health & aging | Issue 2/2020

Abstract

Objectives

Recently, elevated homocysteine was reported to be associated with frailty in cross-sectional studies. However, whether homocysteine is causally associated with frailty is unknown. Here, we explore the inter-relationships between five non-synonymous genetic variants of homocysteine metabolic four genes, plasma homocysteine levels, and frailty.

Method

Data of 1480 individuals aged 70–87 years from the ageing arm of Rugao Longevity and Ageing Study were used. Five variants of the four homocysteine metabolic enzyme genes were genotyped. Frailty was defined using Fried’s phenotype criteria.

Results

The percentage of high homocysteine (>15μmol/L) is 33.3%. Two functional variants that decrease methylenetetrahydrofolate reductase (MTHFR) activities, C677T (Ala222Val, rs1801133) and A1298C (Glu429Ala, rs1801131), were significantly associated with increased homocysteine levels (β=−1.16, p=0.01; and β=1.46, p<0.001, respectively). In addition, homocysteine increase gradually from CC-CC, CC-AC, CT-AC, CT-AA, CC-AA, to TT-AA genotypes of the C677T-A1298C combinations. The five polymorphisms in the homocysteine metabolic gene was not associated with frailty. However, homocysteine was significantly associated with frailty with an OR of 2.27 (95% 1.36–3.78) for high homocysteine after adjusting for multiple confounding factors.

Conclusion

Elevated homocysteine is not a causal factor but a biomarker that manifests greater possibility of frailty in high risk elderly individuals for prevention.

Available only for authorised users

Clegg A, Young J, Iliffe S et al. Frailty in elderly people. Lancet 2013; 381:752–62.PubMed

Morley J E, Vellas B, van Kan G A et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013;14:392–7.PubMedPubMedCentral

Ng T P, Feng L, Nyunt M S et al. Frailty in older persons: multisystem risk factors and the Frailty Risk Index (FRI). J Am Med Dir Assoc 2014;15:635–42.PubMed

Sharma M, Tiwari M, Tiwari R K. Hyperhomocysteinemia: Impact on Neurodegenerative Diseases. Basic Clin Pharmacol Toxicol 2015; 117: 287–96.PubMed

Casas J P, Bautista L E, Smeeth L et al. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005; 365:224–32.PubMed

Larsson S C, Traylor M, Markus H S. Homocysteine and small vessel stroke: A mendelian randomization analysis. Ann Neurol 2019; 85:495–501.PubMedPubMedCentral

Clarke R, Bennett D A, Parish S et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 2012; 9:e1001177.PubMedPubMedCentral

Lacey B, Herrington W G, Preiss D et al. The Role of Emerging Risk Factors in Cardiovascular Outcomes. Curr Atheroscler Rep 2017;19:28.PubMedPubMedCentral

Swart K M, van Schoor N M, Heymans M W et al. Elevated homocysteine levels are associated with low muscle strength and functional limitations in older persons. J Nutr Health Aging 2013; 17: 578–84.PubMed

10.

Vidoni M L, Pettee Gabriel K, Luo S T et al. Vitamin B12 and Homocysteine Associations with Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging. J Nutr Health Aging 2017;21:1321–8.PubMedPubMedCentral

11.

Vidoni M L, Pettee Gabriel K, Luo S T et al. Relationship between Homocysteine and Muscle Strength Decline: The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci 2018 14;73:546–51.PubMed

12.

Wong Y Y, Almeida O P, McCaul K A et al. Homocysteine, Frailty, and All-Cause Mortality in Older Men: The Health in Men Study. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2013; 68: 590–8.

13.

Álvarez-Sánchez N, Álvarez-Ríos A, Guerrero J M et al. Homocysteine and C-reactive protein levels are associated with frailty in older Spaniards: The Toledo Study for Healthy Aging. J Gerontol A Biol Sci Med Sci 2019 Jul 13. pii: glz168. doi: 10.1093/gerona/glz168. [Epub ahead of print].

14.

Frosst P, Blom H J, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–3.PubMed

15.

Friedman G, Goldschmidt N, Friedlander Y et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr 1999;129:1656–61.PubMed

16.

Weisberg I, Tran P, Christensen B et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64:169–72.PubMed

17.

Weiner A S, Boyarskikh U A, Voronina E N et al. Methylenetetrahydrofolate reductase C677T and methionine synthase A2756G polymorphisms influence on leukocyte genomic DNA methylation level. Gene 2014;533:168–72.PubMed

18.

Gaughan D J, Kluijtmans L A, Barbaux S et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001;157:451–6.PubMed

19.

Biselli J M, Zampieri B L, Goloni-Bertollo E M et al. Genetic polymorphisms modulate the folate metabolism of Brazilian individuals with Down syndrome. Mol Biol Rep 2012;39:9277–84.PubMed

20.

Kaul S, Zadeh A A, Shah P K. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 2006;48:914–23.PubMed

21.

Liu Z, Wang Y, Zhang Y et al. Cohort Profile: The Rugao Longevity and Ageing Study (RuLAS). Int J Epidemiol 2016;45:1064–1073.PubMed

22.

Shi G P, Ma T, Zhu Y S et al. Frailty phenotype, frailty index and risk of mortality in Chinese elderly population- Rugao longevity and ageing study. Arch Gerontol Geriatr 2019; 80:115–9.PubMed

23.

Fried L P, Tangen C M, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146–56.PubMed

24.

Blodgett J, Theou O, Kirkland S et al. Frailty in NHANES: Comparing the frailty index and phenotype. Arch Gerontol Geriatr 2015;60:464–70.PubMed

25.

Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142–48.PubMed

26.

Christopher R, Nagaraja D, Shankar S K. Homocysteine and cerebral stroke in developing countries. Curr Med Chem 2007;14:2393–401.PubMed

27.

Kaul S, Zadeh A A, Shah P K. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 2006;48:914–23.PubMed

28.

Chen K, Zhou Y X, Li K et al. A novel three-round multiplex PCR for SNP genotyping with next generation sequencing. Anal Bioanal Chem 2016; 408:4371–7.PubMed

29.

Tsukamoto R, Akisaki T, Kuranaga M et al. Hasegawa Dementia Scale-revised, for screening of early Alzheimer’s disease in the elderly with type 2 diabetes. Geriatr Gerontol Int 2009;9:213–5.PubMed

30.

Foebel A D, Pedersen N L. Genetic Influences on Functional Capacities in Aging. Gerontologist 2016;56 Suppl 2:S218–29.PubMed

31.

Matteini A M, Walston J D, Bandeen-Roche K et al. Transcobalamin-II variants, decreased vitamin B12 availability and increased risk of frailty. J Nutr Health Aging 2010;14:73–7.PubMedPubMedCentral

32.

Zarebska A, Ahmetov II, Sawczyn S et al. Association of the MTHFR 1298A>C (rs1801131) polymorphism with speed and strength sports in Russian and Polish athletes. J Sports Sci 2014;32:375–82PubMed

33.

Swart K M, Enneman A W, van Wijngaarden J P et al. Homocysteine and the methylenetetrahydrofolate reductase 677C—>T polymorphism in relation to muscle mass and strength, physical performance and postural sway. Eur J Clin Nutr 2013;67:743–8.PubMed

34.

Juárez-Cedillo T, Basurto-Acevedo L, Vega-García S et al. Prevalence of anemia and its impact on the state of frailty in elderly people living in the community: SADEM study. Ann Hematol 2014;93:2057–62.PubMed

35.

Kim J, Kim H, Roh H et al. Causes of hyperhomocysteinemia and its pathological significance. Arch Pharm Res 2018;41:372–83.PubMed

36.

ter Borg S, Verlaan S, Hemsworth J et al. Micronutrient intakes and potential inadequacies of community-dwelling older adults: a systematic review. Br J Nutr 2015; 113:1195–206.PubMedPubMedCentral

37.

Sukumar N, Saravanan P. Investigating vitamin B12 deficiency. BMJ 2019; 365: 11865.

38.

Troesch B, Weber P, Mohajeri M H. Potential Links between Impaired One-Carbon Metabolism Due to Polymorphisms, Inadequate B-Vitamin Status, and the Development of Alzheimer’s Disease. Nutrients 2016;8(12). pii: E803.PubMed

39.

Matteini A M, Walston J D, Fallin M D et al. Markers of B-vitamin deficiency and frailty in older women. J Nutr Health Aging 2008;12:303–8.PubMedPubMedCentral

40.

Veeranki S, Tyagi S C. Defective homocysteine metabolism: potential implications for skeletal muscle malfunction. Int J Mol Sci 2013;14:15074–91.PubMedPubMedCentral

41.

Veeranki S, Winchester L J, Tyagi S C. Hyperhomocysteinemia associated skeletal muscle weakness involves mitochondrial dysfunction and epigenetic modifications. Biochim Biophys Acta 2015;1852:732–41.PubMedPubMedCentral

42.

Škovierová H, Vidomanová E, Mahmood S, et al. The Molecular and Cellular Effect of Homocysteine Metabolism Imbalance on Human Health. Int J Mol Sci 2016;17(10). pii: E1733.PubMed

Title: Genetic Variants of Homocysteine Metabolism, Homocysteine, and Frailty - Rugao Longevity and Ageing Study
Authors: T. Ma
X.-H. Sun
S. Yao
Z.-K. Chen
J.-F. Zhang
W. D. Xu
Xiao-Yan Jiang
Xiao-Feng Wang
Publication date: 01-02-2020
Publisher: Springer Paris
Published in: The journal of nutrition, health & aging / Issue 2/2020
Print ISSN: 1279-7707
Electronic ISSN: 1760-4788
DOI: https://doi.org/10.1007/s12603-019-1304-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objectives

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Prevalence of Cognitive Frailty Phenotypes and Associated Factors in a Community-Dwelling Elderly Population

Sensory Impairment and All-Cause Mortality Among the Oldest-Old: Findings from the Chinese Longitudinal Healthy Longevity Survey (CLHLS)

Factors Associated with Frailty Syndrome in Older Adults

Cachexia and Cognitive Function in the Community-Dwelling Older Adults: Mediation Effects of Oral Health

Adherence to a Mediterranean Dietary Pattern and Functional Parameters: A Cross-Sectional Study in an Older Population

The Adverse Effects of Physical Restraint Use among Older Adult Patients Admitted to the Internal Medicine Wards: A Hospital-Based Retrospective Cohort Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials